Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Company Deals

Digital Precision Medicine Secures Over $28 Million in Series C Financing

Fineline Cube Jan 22, 2024

Digital Precision Medicine (DPM), a molecular imaging technology developer incubated by the Chinese Academy of...

Company Drug

NMPA Grants Marketing Approval for Hui Sheng Bio-pharmaceutical’s Janagliflozin

Fineline Cube Jan 22, 2024

The National Medical Products Administration (NMPA) has granted marketing approval for Hui Sheng Bio-pharmaceutical Co.,...

Company Drug

Novartis Lutathera Combo Therapy Shows Significant Progress in GEP-NETs

Fineline Cube Jan 22, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced preliminary results from a Phase III study...

Company Drug

AstraZeneca’s Imfinzi Meets Primary Endpoint in Hepatocellular Carcinoma Trial

Fineline Cube Jan 22, 2024

UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) announced the successful completion of the primary endpoint...

Company Drug

J&J’s Balversa Receives Full FDA Approval for Urothelial Carcinoma Treatment

Fineline Cube Jan 22, 2024

The US Food and Drug Administration (FDA) has converted the 2019 accelerated approval for Johnson...

Policy / Regulatory

Shandong Province Launches Initiatives to Accelerate Pharmaceutical Innovation and Growth

Fineline Cube Jan 22, 2024

Shandong province has announced a comprehensive set of measures aimed at optimizing review and approval...

Company

Everest Medicines Projects Sharp Revenue Increase for 2023 on New Product Launches

Fineline Cube Jan 22, 2024

Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced a preliminary revenue forecast for...

Company Drug

Uni-Bio Science Group Wins NMPA Nod for Generic Forteo Injection for Osteoporosis

Fineline Cube Jan 22, 2024

Hong Kong-listed biopharmaceutical company Uni-Bio Science Group Ltd (HKG: 0690) has announced that it has...

Company Deals

Endoso Life Raises Over $14 Million in Series A to Expand Endoscope Product Lines

Fineline Cube Jan 22, 2024

Endoso Life, a developer of high-end medical endoscope systems headquartered in Hangzhou, has reportedly secured...

Company Deals R&D

Convalife Pharmaceuticals and Divamics Inc. Join Forces to Advance Drug Discovery with AI

Fineline Cube Jan 22, 2024

Convalife Pharmaceuticals, a Shanghai-based clinical pharmaceutical company, and Divamics Inc., a Suzhou-headquartered biopharmaceutical firm specializing...

Company Drug

Sichuan Kelun-Biotech Secures NMPA Nod for Generic Lynparza Equivalent

Fineline Cube Jan 22, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), a Chinese pharmaceutical company, has announced that it...

Company

HighTide Therapeutics to Extend NASH Treatment Reach into Hebei Province

Fineline Cube Jan 22, 2024

HighTide Therapeutics Inc. (HKG: 2511), a China-based non-alcoholic steatohepatitis (NASH) drug developer that recently made...

Company Deals Digital R&D

AI-Driven Biotech Insilico Medicine Teams Up with Hutao Tech for Precision Medicine Robotics

Fineline Cube Jan 22, 2024

Insilico Medicine, a China-based biotech company driven by generative artificial intelligence (AI), has entered into...

Company Drug

InnoCare Makes Minjuvi Combo Treatment Available to Patients in China’s GBA

Fineline Cube Jan 22, 2024

InnoCare (HKG: 9969; SHA: 688428), a China-based biopharmaceutical company, has announced that the combination treatment...

Policy / Regulatory

Guangdong Aims to Boost Biomedicine Industry with Incentives and Strategic Development

Fineline Cube Jan 22, 2024

The Guangdong Provincial Development and Reform Commission has unveiled an ambitious set of measures aimed...

Company Deals

Lee’s Pharmaceutical to Develop Windtree’s Cardiovascular Drugs in Greater China

Fineline Cube Jan 19, 2024

Lee’s Pharmaceutical Ltd (HKG: 0950) has entered into a licensing agreement with US-based Windtree Therapeutics...

Company Drug

BeiGene Submits Additional Application for Tislelizumab in NSCLC in China

Fineline Cube Jan 19, 2024

BeiGene (NASDAQ: BGNE) has announced the submission of a supplementary Biologic License Application in China...

Company Medical Device

Abbott Initiates Clinical Study for Volt PFA System in Australia for Cardiac Arrhythmias

Fineline Cube Jan 19, 2024

Abbott (NYSE: ABT) has announced that the first patients have been treated with its Volt...

Company Deals

AbbVie Grants Enigma Biomedical Group Rights to Next-Generation PET Imaging Biomarkers

Fineline Cube Jan 19, 2024

AbbVie (NYSE: ABBV), a leading pharmaceutical company in the US, has licensed to Canada-based Enigma...

Policy / Regulatory

Sichuan Health Commission Issues Directive to Strengthen Oversight of External Prescriptions

Fineline Cube Jan 19, 2024

The Health Commission of Sichuan Province has issued a notification aimed at enhancing the management...

Posts pagination

1 … 463 464 465 … 717

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.